Gastrointestinal

Peptic ulcer disease: H. pylori testing and treatment regimens

Clinical Overview and When to Suspect Peptic Ulcer Disease

— H. pylori infection (gram-negative, urease-producing spiral bacterium): causes ~70% of gastric ulcers and ~90% of duodenal ulcers in untreated populations

— NSAID/aspirin use: prostaglandin inhibition reduces mucosal defense; risk multiplied by age >65, prior PUD, concurrent steroids/anticoagulants, high-dose or multiple NSAIDs

— Epigastric pain with food relationship (duodenal: relieved by food; gastric: worsened by food)

— Dyspepsia >4 weeks in patient ≥60, or any age with alarm features: weight loss, dysphagia, anemia, melena/hematemesis, persistent vomiting, palpable mass, family history of upper GI cancer

— Iron-deficiency anemia in middle-aged adult without obvious source

— Patient on chronic NSAIDs/aspirin with new epigastric symptoms

Peptic ulcer disease (PUD) = mucosal break ≥5 mm in stomach or duodenum penetrating to submucosa, driven by imbalance between aggressive factors (acid, pepsin, H. pylori, NSAIDs) and mucosal defense (mucus, bicarbonate, prostaglandins, blood flow).

Two dominant etiologies account for >90% of cases:

Less common causes: Zollinger-Ellison syndrome (gastrinoma), stress-related mucosal disease (ICU patients), Crohn disease, viral (CMV, HSV) in immunosuppressed, idiopathic.

When to suspect on Step 3:

Epidemiology: lifetime prevalence ~5–10%; declining in developed countries due to falling H. pylori rates and PPI availability, but rising NSAID-related ulcers in elderly.

Step 3 management: In a patient <60 with uncomplicated dyspepsia and no alarm features, do non-invasive H. pylori test-and-treat (urea breath test or stool antigen) rather than empiric PPI or upfront endoscopy — this is the cost-effective ambulatory pathway emphasized on the exam.

Board pearl: Duodenal ulcers are almost never malignant; gastric ulcers require biopsy to exclude adenocarcinoma and follow-up endoscopy to confirm healing.

Presentation Patterns and Key History

— Duodenal ulcer: pain 2–5 hours postprandial, relieved by food or antacids; patients often gain weight

— Gastric ulcer: pain shortly after eating, worsened by food; patients may avoid eating and lose weight

— Vomiting persistent/recurrent

— Bleeding (melena, hematemesis, hematochezia from brisk UGIB)

— Anemia (iron-deficiency)

— Dysphagia/odynophagia

— Mass (palpable abdominal or lymphadenopathy)

— Age ≥60 with new-onset dyspepsia

— Progressive unintentional weight loss

— NSAID/aspirin use (including OTC, prescription, herbals containing salicylates) — quantify daily dose and duration

— H. pylori risk factors: birth/residence in endemic area, crowded housing, family history of gastric cancer

— Smoking and alcohol (impair healing, increase recurrence)

— Anticoagulants, SSRIs, bisphosphonates, steroids — all increase bleeding/ulcer risk

— Prior PUD or H. pylori treatment and which regimen (predicts resistance)

Classic dyspepsia: epigastric burning, gnawing, or hunger-like pain, often episodic over weeks to months, with nocturnal awakening (2–3 AM) being highly suggestive of duodenal ulcer.

Food–pain timing (imperfect but tested):

Associated symptoms: bloating, early satiety, nausea, belching, fatty food intolerance — overlap heavily with functional dyspepsia and GERD.

Alarm features ("VBAD MAP") demanding urgent EGD regardless of age:

Targeted history must capture:

Atypical/silent presentations: elderly and chronic NSAID users may present with complications first — bleeding, perforation, or obstruction — without antecedent pain. Up to half of NSAID ulcers are asymptomatic until they bleed.

Key distinction: Cardiac ischemia can masquerade as epigastric "indigestion" — in any patient ≥50 or with risk factors presenting with new epigastric pain, obtain an ECG before anchoring on PUD, especially if pain is exertional or associated with diaphoresis.

Board pearl: A patient with recurrent ulcers refractory to standard therapy, multiple/distal duodenal ulcers, or ulcers with diarrhea → think Zollinger-Ellison and check fasting serum gastrin off PPI.

Physical Exam Findings and Hemodynamic Assessment

— Localized epigastric tenderness without peritoneal signs in uncomplicated disease

— Succussion splash (audible splash on shaking abdomen 3+ hours postprandial) → gastric outlet obstruction from chronic scarring of pyloric channel ulcer

— Rigid, board-like abdomen with rebound and guarding → perforated ulcer with peritonitis — surgical emergency

— Diminished/absent bowel sounds with distention → ileus from perforation or obstruction

— Melena: black tarry stool requires ≥50 mL blood; very specific for upper source

— Hematemesis or "coffee-ground" emesis

— Hematochezia in setting of brisk UGIB indicates massive bleed (≥1000 mL) with rapid transit

— Pallor, conjunctival rim pallor, cool extremities, delayed cap refill

— HR >100, SBP <100, orthostatic drop (SBP ↓≥20 or HR ↑≥20 on standing) → significant volume loss (≥15–30%)

— Shock index (HR/SBP) ≥1.0 predicts need for transfusion and intervention

— Mental status changes, oliguria → class III–IV shock

Uncomplicated PUD: exam is often unremarkable beyond mild epigastric tenderness to deep palpation; absence of findings does not exclude disease.

Focused abdominal exam:

Signs of upper GI bleeding (bleeding ulcer is the #1 cause of UGIB):

Hemodynamic assessment — Step 3 priority:

CCS pearl: For suspected bleeding ulcer, your first orders are: two large-bore IVs (16–18g), CBC, type & crossmatch (≥2 units PRBC), coags/INR, BMP, LFTs, lactate, NPO, IV PPI bolus + infusion, IV crystalloid resuscitation, and GI consult for urgent EGD within 24 hours. Do not delay endoscopy waiting for NG lavage — it's no longer recommended.

Board pearl: BUN/Cr ratio >30 in a bleeding patient suggests upper GI source (digested blood as protein load) and helps localize before scope. A rectal exam confirming melena is mandatory in any anemic or hemodynamically suspicious patient — don't skip it.

Diagnostic Workup — Initial Labs and Non-Invasive H. pylori Testing

— CBC (anemia from occult blood loss)

— BMP (BUN/Cr ratio, electrolytes if vomiting)

— Iron studies if anemic (microcytic, low ferritin <30)

— Pregnancy test in reproductive-age women (alters testing/treatment)

— Consider lipase, LFTs, ECG to rule out mimics

— Urea breath test (UBT): patient drinks 13C- or 14C-labeled urea; H. pylori urease cleaves it → labeled CO2 in breath. Sensitivity & specificity >95%. First-line for active infection and test of cure.

— Stool antigen test (monoclonal EIA): sensitivity ~94%, specificity ~97%. Equivalent to UBT; cheaper, good in children and when breath test unavailable.

— Serology (IgG antibodies): detects exposure, cannot distinguish active from past infection, remains positive for years. Use only in low-prevalence settings is discouraged; reasonable in very high-prevalence populations or recent UGIB where PPI confounds other tests.

— Hold PPI for ≥2 weeks before UBT or stool antigen

— Hold antibiotics and bismuth for ≥4 weeks

— H2 blockers OK to continue (minimal effect on testing)

— Active or past PUD (any documented ulcer)

— Uninvestigated dyspepsia in patient <60 without alarm features (test-and-treat)

— Low-grade gastric MALT lymphoma

— Early gastric cancer post-resection

— Long-term NSAID/aspirin users (selective)

— Unexplained iron-deficiency anemia, ITP, vitamin B12 deficiency

Routine labs in dyspepsia/suspected PUD:

Non-invasive H. pylori testing — three validated options:

Critical pre-test preparations (false negatives):

Who gets tested? ACG: test only patients you intend to treat. Indications:

Step 3 management: Patient <60 with uncomplicated dyspepsia → non-invasive H. pylori test → treat if positive → confirm eradication 4+ weeks after therapy with UBT or stool antigen. Avoid serology unless other tests unavailable.

Board pearl: Continued PPI use is the #1 cause of false-negative H. pylori testing. If patient can't stop PPI (e.g., recent bleed), use biopsy-based testing (histology or rapid urease test) at endoscopy, or serology as last resort.

Diagnostic Workup — Endoscopy and Biopsy-Based Testing

— Any alarm features regardless of age

— Age ≥60 with new-onset dyspepsia

— Failed empiric or test-and-treat therapy (persistent symptoms after 4–8 weeks)

— Suspected complication (bleeding, obstruction, perforation pending stability)

— Known gastric ulcer (always biopsy to exclude malignancy)

— Rapid urease test (CLO test): biopsy placed in urea-containing media; color change from urease activity. Sensitivity ~90%, specificity ~95%. Cheap and fast. False negatives with recent PPI, antibiotics, bismuth, or active bleeding.

— Histology with H&E + special stains (Giemsa, silver): sensitivity ~95%, also evaluates for gastritis, atrophy, intestinal metaplasia, MALT, malignancy.

— Culture with susceptibility testing: gold standard for resistance assessment; reserved for refractory cases or research; slow and not widely available.

— Molecular testing (PCR for clarithromycin/levofloxacin resistance mutations): emerging standard for resistance-guided therapy.

— Gastric ulcers: multiple biopsies (≥6–8) from edge and base to exclude adenocarcinoma; repeat EGD in 8–12 weeks to confirm healing

— Duodenal ulcers: routine biopsy not required (rarely malignant); biopsy antrum + body for H. pylori

Upper endoscopy (EGD) is the gold standard for PUD diagnosis: directly visualizes ulcer, allows biopsy, and enables hemostatic therapy.

Indications for EGD in suspected PUD:

Biopsy-based H. pylori tests (perform during EGD):

Biopsy protocol for ulcers:

For H. pylori detection at EGD: take biopsies from both antrum and corpus (patchy distribution; PPI use shifts H. pylori to corpus, causing false negatives if only antrum sampled).

CCS pearl: In a hemodynamically stable bleeding ulcer patient, EGD within 24 hours is the target. Earlier (<12 hours) is not better for most patients and may increase complications. Resuscitate first, then scope.

Board pearl: Active GI bleeding reduces sensitivity of all H. pylori tests (urease, histology, antigen). If initial test is negative in a bleeding ulcer, repeat testing 4–8 weeks later before declaring patient H. pylori-negative — missed infection drives recurrence.

Risk Stratification and Management Logic

— Alarm features OR age ≥60 → EGD first

— Age <60, no alarms → non-invasive H. pylori test-and-treat

— If H. pylori negative and symptoms persist → empiric PPI trial 4–8 weeks → if still symptomatic, EGD

— H. pylori positive: eradication therapy + PPI 4–8 weeks → confirm eradication

— NSAID-induced, H. pylori negative: discontinue NSAID + PPI 4–8 weeks

— NSAID-induced, H. pylori positive: treat both — eradicate H. pylori AND stop NSAID + PPI

— Idiopathic (neither): PPI; consider gastrinoma workup if multiple/refractory

— Uses BUN, Hgb, SBP, HR, melena, syncope, hepatic disease, heart failure

— GBS = 0–1: very low risk; consider outpatient management with early outpatient EGD

— GBS ≥7: high risk for intervention; admit + urgent EGD

— Ia (spurting), Ib (oozing), IIa (visible vessel), IIb (adherent clot) → endoscopic therapy + IV PPI infusion 72h

— IIc (flat pigmented spot), III (clean base) → low rebleed risk; oral PPI, early feeding, discharge possible

Initial fork in the road — patient with dyspepsia:

Once ulcer confirmed, stratify by etiology because treatment differs:

Bleeding ulcer risk stratification — Glasgow-Blatchford Score (GBS):

Forrest classification (endoscopic appearance, predicts rebleeding):

Rockall score (post-endoscopic) predicts mortality and rebleeding; combines age, shock, comorbidity, diagnosis, stigmata of bleeding.

Step 3 management: A patient with low Glasgow-Blatchford score (0–1), stable vitals, no comorbidity, and reliable follow-up can be discharged from the ED with outpatient EGD — a frequently tested cost-effective decision.

Board pearl: Pre-endoscopy IV PPI (80 mg bolus + 8 mg/h infusion OR 80 mg bolus + 40 mg BID) downstages endoscopic lesions and reduces need for endoscopic therapy but does not affect mortality. Start it as soon as UGIB suspected — don't wait for EGD.

Pharmacotherapy — H. pylori Eradication Regimens

— Bismuth quadruple therapy (preferred first-line per ACG 2017) — 14 days:

PPI BID + bismuth subsalicylate 524 mg QID + tetracycline 500 mg QID + metronidazole 250–500 mg QID

Use when clarithromycin resistance >15%, prior macrolide exposure, or penicillin allergy. Eradication ~85–90%.

— Clarithromycin triple therapy — 14 days:

PPI BID + clarithromycin 500 mg BID + amoxicillin 1 g BID (or metronidazole 500 mg BID if PCN-allergic)

Use only if local clarithromycin resistance <15% AND no prior macrolide exposure. Eradication is dropping (~70–80%) due to resistance — no longer preferred in most US regions.

— Concomitant therapy — 10–14 days: PPI + clarithromycin + amoxicillin + metronidazole (all together). Reasonable when bismuth unavailable.

— Vonoprazan-based regimens (potassium-competitive acid blocker): vonoprazan + amoxicillin (dual) or + clarithromycin (triple) x 14 days — superior acid suppression, better in clarithromycin-resistant strains

— Rifabutin triple therapy (Talicia: omeprazole + amoxicillin + rifabutin) — salvage option

— Never repeat clarithromycin or levofloxacin if used previously (high resistance after exposure)

— Bismuth quadruple if not used first-line

— Levofloxacin triple: PPI + levofloxacin 500 mg daily + amoxicillin 1 g BID x 14 days

— Rifabutin-based regimen

— Refer to GI; consider culture with susceptibility testing

First-line regimens depend on local clarithromycin resistance and prior macrolide exposure:

Newer FDA-approved options:

Salvage therapy after failure:

Confirm eradication in ALL treated patients with urea breath test or stool antigen ≥4 weeks after completion and ≥2 weeks off PPI. Serology is not valid for test of cure.

Step 3 management: Default to bismuth quadruple therapy x 14 days in the US unless you can verify low local clarithromycin resistance and confirm no prior macrolide use — this is the safest exam answer in 2024.

Board pearl: Adherence is the #1 modifiable determinant of eradication. Counsel about bismuth turning stool/tongue black (not bleeding!), metronidazole–alcohol disulfiram-like reaction, and tetracycline photosensitivity. 14-day courses outperform 7–10 day courses.

Adjunctive Pharmacology — Acid Suppression and Mucosal Protection

— Mechanism: irreversibly bind H+/K+-ATPase on parietal cells; require activation in acidic environment → take 30–60 minutes before meals (typically breakfast)

— Standard agents: omeprazole 20–40 mg, pantoprazole 40 mg, lansoprazole 30 mg, esomeprazole 20–40 mg, rabeprazole 20 mg

— Duration for PUD: duodenal ulcer 4 weeks, gastric ulcer 8 weeks

— IV PPI (pantoprazole) for bleeding ulcers: 80 mg bolus + 8 mg/h infusion x 72h post-endoscopic hemostasis, or intermittent 40 mg IV BID

— B12, magnesium, iron, calcium malabsorption

— Increased risk of C. difficile, community-acquired pneumonia, enteric infections

— Possible association: hip fracture, AKI/CKD, dementia, fundic gland polyps

— Rebound hyperacidity on abrupt discontinuation

— Sucralfate: binds ulcer base; QID dosing on empty stomach; binds other meds (separate by 2h); useful in stress ulcer prophylaxis and selected refractory cases

— Misoprostol (synthetic PGE1): prevents NSAID ulcers; QID dosing limits use; contraindicated in pregnancy (abortifacient)

— Bismuth subsalicylate: cytoprotective + antibacterial; avoid in renal failure and aspirin allergy

— Co-prescribe PPI daily with NSAID

— Consider COX-2 selective (celecoxib) + PPI in highest risk — but weigh CV risk

— Test and eradicate H. pylori before starting long-term NSAID/aspirin in PUD history

Proton pump inhibitors (PPIs) — cornerstone of ulcer healing:

PPI long-term risks (counsel and weigh against benefit):

H2 receptor antagonists (famotidine, nizatidine): less potent than PPI; reasonable for mild symptoms, on-demand use, or PPI intolerance. Develop tachyphylaxis within weeks.

Mucosal protective agents:

NSAID-related PUD prevention in high-risk patients (prior ulcer, age >65, anticoagulants, steroids):

CCS pearl: In a bleeding ulcer with high-risk stigmata (Forrest Ia–IIb) after endoscopic therapy, order continuous IV PPI x 72h, then transition to oral BID PPI x 2 weeks, then daily for total 8 weeks. Keep NPO 24h, then advance diet.

Board pearl: PPIs are more effective than H2 blockers for both ulcer healing and bleeding prevention. Don't substitute famotidine when a PPI is indicated.

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher prevalence of NSAID use (osteoarthritis, cardiovascular indications) and antiplatelet/anticoagulant therapy

— Asymptomatic ulcers until bleeding or perforation — diminished pain perception

— Higher mortality from UGIB (5–10% vs 2% overall)

— Lower threshold for EGD (any new dyspepsia ≥60 = scope)

— Identify NSAIDs (including OTC ibuprofen, naproxen, topical, combination cold remedies)

— Deprescribe when possible; substitute acetaminophen for analgesia

— If NSAID essential: lowest dose, shortest duration, co-prescribe PPI, eradicate H. pylori first

— Review anticoagulants, antiplatelets, SSRIs, steroids, bisphosphonates — additive risk

— Avoid bismuth and magnesium-containing antacids in advanced CKD (accumulation, encephalopathy, hypermagnesemia)

— Clarithromycin: reduce dose if CrCl <30 mL/min

— Tetracycline: avoid in significant renal impairment; doxycycline not a validated substitute in standard regimens but sometimes used

— Metronidazole: no renal dose adjustment; reduce if HD (administer after dialysis)

— Amoxicillin: dose-adjust if CrCl <30

— PPIs: no renal dose adjustment, but monitor for acute interstitial nephritis (idiosyncratic)

— Metronidazole: reduce dose in severe hepatic failure

— Clarithromycin and PPIs: hepatically metabolized — use cautiously, prefer pantoprazole (less CYP interaction)

— Bismuth: caution given salicylate component

— Clarithromycin + statins (rhabdo), warfarin (↑INR), QT-prolonging drugs, calcium channel blockers

— PPIs + clopidogrel (omeprazole/esomeprazole reduce clopidogrel activation via CYP2C19 — prefer pantoprazole)

— Tetracycline chelates Ca, Mg, Fe, Al — separate from antacids/dairy by 2 hours

Elderly patients carry disproportionate PUD morbidity:

Polypharmacy review is mandatory at every visit:

Renal impairment:

Hepatic impairment:

Drug interactions to flag:

Step 3 management: In an elderly patient on aspirin or DOAC who develops PUD, do not stop antithrombotic indefinitely — restart within 7 days of hemostasis once endoscopic bleeding risk is low; continued discontinuation increases cardiovascular and thromboembolic mortality.

Board pearl: A patient on clopidogrel needing acid suppression → pantoprazole is the safest choice; rabeprazole and famotidine are alternatives.

Special Populations — Pregnancy, Pediatrics, and Immunocompromised

— PUD is uncommon in pregnancy (protective hormonal effects, ↑mucus production)

— Diagnosis: avoid radiation; EGD is safe in 2nd trimester if essential; non-invasive H. pylori testing via stool antigen preferred (UBT uses 13C — safe; 14C contraindicated)

— Treatment of PUD:

Lifestyle, antacids (Ca-based preferred), sucralfate (category B) first-line

PPIs: most considered low-risk; pantoprazole and lansoprazole widely used; avoid omeprazole if alternatives exist (older Category C)

H2 blockers: famotidine safe in pregnancy

— Defer H. pylori eradication until postpartum unless complicated disease, because:

Tetracycline contraindicated (teratogenic, fetal bone/teeth)

Bismuth contraindicated (salicylate component, fetal hemorrhage)

Clarithromycin: avoid in 1st trimester

Metronidazole: avoid 1st trimester per traditional teaching; safer later

— Misoprostol absolutely contraindicated (uterotonic, abortifacient)

— H. pylori acquired in childhood, often asymptomatic

— Test only with documented PUD or refractory IDA — "test and treat" not recommended in asymptomatic children

— Use biopsy-based testing during EGD (preferred) or stool antigen

— Regimen: PPI + amoxicillin + clarithromycin x 14 days (weight-based); avoid tetracycline in <8 years and bismuth controversial

— Avoid serology (poor performance in children)

— Consider CMV, HSV, fungal ulcers in addition to H. pylori — biopsy critical

— Drug interactions: clarithromycin with tacrolimus, cyclosporine, HIV protease inhibitors

— Higher UGIB risk (varices coexist); always differentiate variceal vs ulcer bleeding at EGD

— Avoid NSAIDs entirely (renal + bleeding risk)

Pregnancy:

Pediatrics:

Immunocompromised hosts (HIV, transplant, chemotherapy):

Patients with cirrhosis:

Board pearl: In pregnancy, the answer for symptomatic PUD is usually sucralfate or a PPI (pantoprazole/lansoprazole), with H. pylori eradication deferred to postpartum. Memorize that tetracycline and bismuth are pregnancy contraindicated.

Step 3 management: A pregnant patient with PUD-like symptoms and positive stool H. pylori antigen → treat with lifestyle + sucralfate/PPI now; postpartum, give bismuth quadruple x 14 days and confirm eradication after weaning if breastfeeding contraindications.

Complications and Adverse Outcomes

— Posterior duodenal bulb ulcers erode into gastroduodenal artery → brisk hematemesis/melena

— Lesser curve gastric ulcers erode into left gastric artery

— Management: resuscitate, IV PPI, EGD with dual hemostatic therapy (epinephrine + thermal/clip), angioembolization if refractory, surgery as last resort

— 30-day mortality 2–10%; rebleeding rate 10–20% with high-risk stigmata

— Sudden severe epigastric pain, rigid abdomen, tachycardia, fever

— Free air under diaphragm on upright CXR (~75% sensitive); CT abdomen more sensitive

— Treatment: IV fluids, broad-spectrum antibiotics (cover gram-negatives + anaerobes — e.g., piperacillin-tazobactam), PPI, emergent surgery (Graham omental patch is classic for duodenal perforation); H. pylori eradication post-op if positive

— Mortality 10–25%, higher in elderly with delayed surgery

— Persistent pain radiating to back, elevated lipase mimicking pancreatitis

— Diagnose with CT or EGD; intensive medical therapy may suffice; surgery if refractory

— Chronic pyloric channel or duodenal ulcer scarring

— Postprandial nonbilious vomiting, early satiety, weight loss, succussion splash

— Hypochloremic, hypokalemic metabolic alkalosis with paradoxical aciduria

— Diagnose with EGD ± gastric emptying study

— Treatment: NG decompression, IV fluids/electrolyte repletion, IV PPI, eradicate H. pylori, endoscopic balloon dilation of strictures; surgery (pyloroplasty, gastrojejunostomy) for refractory

Four classical complications (memorize "BOPP"): Bleeding, Obstruction, Penetration, Perforation.

Bleeding (most common, ~15% of PUD patients):

Perforation (2–10%):

Penetration (into adjacent organ — pancreas most common):

Gastric outlet obstruction (1–2%):

Malignancy (gastric ulcers): exclude with biopsies + repeat EGD at 8–12 weeks to confirm healing.

Long-term consequences: chronic iron-deficiency anemia, recurrence (5–20% even after H. pylori eradication, mostly NSAID-driven), gastric atrophy/intestinal metaplasia in chronic H. pylori → adenocarcinoma and MALT lymphoma risk.

CCS pearl: In suspected perforated ulcer, your first orders are: NPO, NG tube, IVF, IV PPI, IV antibiotics (pip-tazo), CBC/BMP/lactate/T&S, upright CXR + CT abdomen/pelvis with IV contrast, stat surgery consult. Don't waste time on EGD — it's contraindicated.

Board pearl: Hypokalemic, hypochloremic metabolic alkalosis with paradoxical aciduria = gastric outlet obstruction until proven otherwise.

When to Escalate Care — ICU, Consult, and Inpatient Triage

— Uncomplicated dyspepsia or PUD without alarms

— Glasgow-Blatchford score 0–1 in mild UGIB with reliable follow-up

— Stable post-discharge after low-risk endoscopic findings (Forrest IIc/III)

— Symptomatic anemia from chronic GI loss requiring transfusion

— Hemodynamically stable UGIB after resuscitation with high-risk lesion treated endoscopically

— Inability to tolerate POs (vomiting, partial obstruction)

— Significant comorbidity preventing safe outpatient EGD

— Hemodynamic instability after initial resuscitation (persistent SBP <90 or HR >120)

— Active hematemesis with airway concern → consider intubation for airway protection before EGD

— Massive transfusion (≥4 units PRBC in 24h)

— Variceal vs. ulcer bleeding unclear in cirrhotic

— Forrest Ia/Ib lesions post-endoscopic therapy, hemodynamic borderline

— Gastroenterology: every confirmed/suspected bleeding ulcer; refractory dyspepsia, suspected ZES, MALT lymphoma

— Interventional radiology: persistent/recurrent bleeding despite endoscopic therapy (angiography + embolization, especially gastroduodenal artery)

— General surgery: perforation (emergent), refractory bleeding after 2 failed endoscopic attempts, gastric outlet obstruction not responsive to dilation, suspected malignancy

— Hematology: massive transfusion, suspected coagulopathy beyond anticoagulation reversal

— Cardiology: if interrupting antiplatelet after DES <12 months or recent ACS

— Transfuse Hgb <7 g/dL in most patients

— Hgb <8 g/dL if CAD, hemodynamic instability, ongoing brisk bleeding

— Target Hgb 7–9, not >10 (over-transfusion worsens outcomes)

— Warfarin: vitamin K + 4-factor PCC if life-threatening

— Dabigatran: idarucizumab

— Factor Xa inhibitors: andexanet alfa or 4-factor PCC

Outpatient management is appropriate for:

Admit to general medical floor:

Admit to ICU/step-down:

Consultations:

Transfusion thresholds in UGIB (restrictive strategy reduces mortality):

Reversal of anticoagulants in bleeding PUD:

Step 3 management: Don't delay EGD waiting to normalize INR perfectly — INR up to ~2.5 is acceptable for endoscopic intervention; over-correction risks thrombosis.

CCS pearl: Time-sensitive simulated orders: IV access x2, T&C, IV PPI, restrictive transfusion goal, GI consult — all within the first hour of presentation.

Key Differentials — Same-Category (Upper GI) Causes

— Chronic epigastric pain, postprandial fullness, early satiety without structural lesion at EGD

— Rome IV criteria; diagnosis after H. pylori excluded and treated, PUD excluded

— Treatment: PPI trial, tricyclic antidepressants (amitriptyline low-dose), prokinetics

— Heartburn, regurgitation, worsened recumbent/postprandial, relieved by acid suppression

— Overlaps with PUD; PPI trial helps differentiate

— Alarm features → EGD

— Mucosal inflammation without discrete ulcer ≥5 mm

— Causes: NSAIDs, alcohol, stress (ICU patients), H. pylori

— Always exclude in gastric ulcer with biopsies + repeat EGD

— Risk: H. pylori chronic infection, atrophic gastritis, intestinal metaplasia, smoking, family history, pernicious anemia

— Linitis plastica = diffuse infiltrative variant

— H. pylori-driven in 90% of cases

— Low-grade MALT often regresses with H. pylori eradication alone — confirmed by post-treatment endoscopy

— Multiple/recurrent/distal duodenal or jejunal ulcers; refractory to standard therapy

— Diarrhea, steatorrhea (acid inactivates pancreatic enzymes)

— Fasting serum gastrin >1000 pg/mL off PPI (hold PPI 1 week, H2 blocker 2 days) is diagnostic; if 100–1000, do secretin stimulation test (paradoxical rise)

— Associated with MEN1 (parathyroid, pancreas, pituitary) in 25%

Functional dyspepsia (most common):

Gastroesophageal reflux disease (GERD):

Erosive gastritis/duodenitis:

Gastric adenocarcinoma:

Gastric lymphoma (MALT):

Zollinger-Ellison syndrome (gastrinoma):

Eosinophilic gastritis/gastroenteritis: peripheral eosinophilia, allergic history, biopsy diagnosis.

Crohn disease of upper GI tract: rare; aphthous ulcers, cobblestoning, granulomas on biopsy.

Cameron lesions: linear ulcers within hiatal hernia sac causing chronic anemia.

Key distinction: Gastric ulcer + biopsy showing signet ring cells = adenocarcinoma. Gastric ulcer + dense lymphoid infiltrate with lymphoepithelial lesions = MALT lymphoma — test for H. pylori; eradication is first-line therapy for stage I/II low-grade disease.

Board pearl: Suspect ZES in (a) ulcers in unusual locations (distal duodenum, jejunum), (b) multiple ulcers, (c) ulcers refractory to high-dose PPI, (d) ulcers with diarrhea, or (e) PUD plus hypercalcemia (MEN1 clue).

Key Differentials — Other-Category Causes of Epigastric Pain

— Acute coronary syndrome (especially inferior MI): can present as epigastric pain, nausea, diaphoresis. Always ECG in patients ≥50 or with risk factors and new epigastric symptoms.

— Pericarditis, aortic dissection (radiates to back, BP differential between arms)

— Acute pancreatitis: epigastric pain radiating to back, lipase >3x ULN, alcohol/gallstone history

— Chronic pancreatitis: deep boring pain, steatorrhea, calcifications on CT

— Cholecystitis/biliary colic: RUQ/epigastric, postprandial (fatty meal), Murphy sign, US findings

— Choledocholithiasis/cholangitis: jaundice, Charcot triad

— Pancreatic cancer: weight loss, painless jaundice (head), back pain (body/tail), new-onset diabetes

— Hepatitis, hepatic congestion (RHF), hepatic abscess

— Mesenteric ischemia: postprandial pain "fear of food," weight loss in chronic; acute = pain out of proportion to exam, lactic acidosis, AFib history

— AAA: pulsatile mass, hypotension, back pain — emergency

— DKA: nausea/vomiting, abdominal pain, hyperglycemia, anion gap acidosis

— Adrenal insufficiency: nausea, hypotension, hyponatremia

— Hypercalcemia: nausea, pain, constipation

Cardiac:

Pancreaticobiliary:

Hepatic:

Mesenteric/vascular:

Renal/urologic: pyelonephritis, nephrolithiasis (radiates to groin)

Pulmonary: lower lobe pneumonia, pulmonary embolism with diaphragmatic irritation

Endocrine/metabolic:

Functional/psychiatric: somatic symptom disorder, anxiety; diagnosis of exclusion

Medication/toxic: bisphosphonates (esophagitis/ulcer), iron supplements, KCl tablets, NSAIDs, cocaine-related mesenteric ischemia

Gynecologic (in women): ectopic pregnancy, ovarian torsion can refer pain upward

Step 3 management: A 55-year-old with new "indigestion," diaphoresis, and risk factors → ECG + troponin before PPI trial. Missing inferior MI by anchoring on PUD is a classic test trap and a real-world malpractice scenario.

Board pearl: Pain out of proportion to exam in elderly with vascular disease → mesenteric ischemia, not PUD. Get a CT angiogram and lactate.

Secondary Prevention and Long-Term Plan

— UBT or stool antigen ≥4 weeks after antibiotics complete and ≥2 weeks off PPI

— Serology not valid (stays positive)

— Re-treatment with salvage regimen if persistent infection — do not repeat prior antibiotics

— Discontinue NSAID if at all possible; switch to acetaminophen

— If NSAID essential (e.g., RA, severe OA): use lowest effective dose, shortest duration, add daily PPI indefinitely, eradicate H. pylori first

— Consider COX-2 selective (celecoxib) + PPI in highest-risk patients; weigh cardiovascular risk

— Avoid concurrent aspirin, anticoagulants, steroids when possible

— Resume aspirin within 1–7 days of hemostasis if indicated for secondary CV prevention — sustained discontinuation increases CV mortality

— Continue daily PPI long-term when aspirin + PUD history coexist

— Smoking cessation (delays healing, doubles recurrence)

— Alcohol moderation

— Stress management; address anxiety/depression contributing to dyspepsia

— Avoid NSAIDs as discussed; counsel on hidden OTC sources

— All gastric ulcers: repeat EGD 8–12 weeks post-treatment to confirm healing and re-biopsy if not healed (malignancy)

— Duodenal ulcers: routine repeat EGD not needed if H. pylori eradicated and symptoms resolved

— Recurrent/refractory ulcers → reassess for ZES, ongoing NSAID use, persistent H. pylori

— Patients with atrophic gastritis, intestinal metaplasia, or dysplasia on biopsy → endoscopic surveillance per ACG (every 3–5 years depending on severity)

— After ulcer healing in H. pylori-eradicated, non-NSAID patients, taper PPI rather than abrupt stop

— Continue indefinitely if ongoing NSAID/aspirin, severe GERD, Barrett esophagus, ZES

Confirm H. pylori eradication in all treated patients:

NSAID management post-ulcer:

Aspirin for cardiovascular prevention after bleeding ulcer:

Anticoagulants: same logic — restart early after hemostasis (typically within 7 days), co-prescribe PPI; consider DOAC over warfarin if appropriate.

Lifestyle modifications:

Repeat EGD indications:

Gastric cancer surveillance:

PPI deprescribing when appropriate:

Step 3 management: Patient with recent bleeding ulcer on aspirin for prior MI → resume aspirin within 1–3 days of hemostasis + lifelong daily PPI. Counsel that stopping aspirin permanently increases MI/death more than rebleeding risk.

Board pearl: Always confirm H. pylori eradication — symptomatic resolution does not equal cure, and persistent infection drives recurrence and cancer risk.

Follow-Up, Monitoring, and Counseling

— 2–4 weeks after starting eradication: assess symptom response, adherence, adverse effects

— 4–8 weeks post-therapy: test of cure (UBT or stool antigen, off PPI ≥2 weeks)

— 8–12 weeks for gastric ulcers: repeat EGD with biopsies to confirm healing and exclude malignancy

— Annual follow-up for NSAID users, patients with atrophic gastritis or metaplasia, cancer surveillance per pathology

— Symptom resolution: dyspepsia, pain, regurgitation

— Iron studies and Hgb: ensure resolution of any anemia from chronic losses; supplement iron 3–6 months until ferritin normalizes

— Renal function and magnesium on chronic PPI: BMP + Mg yearly; consider B12 every 1–2 years

— Treatment adherence: explicitly ask about completing 14-day antibiotic course

— Take PPI 30–60 minutes before breakfast (and dinner if BID) — efficacy depends on this

— Complete full 14 days of antibiotics even when symptoms resolve

— Expect black stool/tongue with bismuth (benign)

— Avoid alcohol with metronidazole (disulfiram-like reaction)

— Photosensitivity with tetracycline — sunscreen, protective clothing

— Avoid antacids within 2 hours of tetracycline (chelation)

— Hematemesis, melena, hematochezia

— Severe abdominal pain, rigid abdomen, syncope

— Persistent vomiting, inability to keep down fluids

— Unintentional weight loss, progressive dysphagia

— Cost: bismuth quadruple ~$100–200; vonoprazan combos higher; consider patient access

— Use prescription drug coverage tools and patient assistance programs

— Coordinate with PCP for chronic PPI monitoring and NSAID deprescribing

— Smoking cessation referral (nicotine replacement, varenicline, bupropion)

— Alcohol use screening (AUDIT-C); brief intervention

— Stress reduction; CBT if functional overlap

Outpatient follow-up cadence:

Monitoring parameters:

Counseling at discharge/return visit:

Return precautions — instruct to seek care for:

Health systems considerations:

Lifestyle counseling:

CCS pearl: Schedule the test of cure visit at the same time you prescribe eradication therapy — patients often skip it, and unconfirmed eradication is the #1 cause of "recurrence."

Board pearl: A patient asking "why am I still on this PPI a year later?" with no NSAID/aspirin/GERD/Barrett indication → taper and discontinue; chronic PPI without indication is a quality-of-care issue.

Ethical, Legal, and Patient Safety Considerations

— Discuss risks: perforation (<0.1%), bleeding, infection, sedation-related cardiopulmonary events, missed lesions, anesthesia risk in comorbid patients

— Discuss benefits: diagnosis, biopsy, therapeutic intervention

— Discuss alternatives: empiric PPI, non-invasive testing

— Capacity assessment: ensure patient understands; if impaired, involve surrogate per state hierarchy

— Patient with severe arthritis insisting on NSAIDs despite ulcer history → document risk discussion, alternatives offered, co-prescribed PPI, and ongoing reassessment

— Respect autonomy while ensuring informed choice

— Stopping aspirin after recent DES (<12 months) or ACS without cardiology input can cause fatal stent thrombosis — always coordinate

— Document the risk-benefit conversation

— Patients discharged after bleeding ulcer often have fragmented follow-up — missed test-of-cure visits, missed repeat EGD for gastric ulcer healing, premature PPI discontinuation

— Ensure closed-loop communication: discharge summary to PCP, scheduled follow-up before discharge, medication reconciliation, written instructions in plain language at appropriate literacy

— Medication reconciliation: NSAIDs hidden in OTC combinations, herbal products; explicitly review at every transition

— Inappropriate long-term PPI without indication = deprescribing opportunity

— Hospital-acquired stress ulcer prophylaxis overuse: limit to high-risk ICU patients (mechanical ventilation >48h, coagulopathy, history of GI bleed)

— Avoid continuing inpatient PPI prophylaxis on discharge unless ongoing indication — a common error

— Suspected intimate partner violence in patient presenting with vague abdominal complaints and inconsistent history — screen and report per jurisdiction

— Pediatric/elder abuse with unusual injury patterns

— H. pylori prevalence higher in immigrant, low-income, and minority populations — ensure equitable screening and treatment access

— Language-concordant care and certified medical interpreters required for informed consent (NOT family members for sensitive discussions)

Informed consent for EGD:

Shared decision-making in chronic NSAID use:

Antiplatelet/anticoagulant decisions are high-stakes:

Transitions of care risks (Step 3 favorite):

Quality and safety metrics:

Mandatory reporting/legal:

Health equity:

Step 3 management: A patient post-discharge for bleeding ulcer with no scheduled GI follow-up represents a safety gap — the responsible inpatient team must arrange and document the follow-up appointment before discharge, not leave it to the patient or PCP to chase.

Board pearl: Stopping aspirin permanently after a bleeding ulcer in a patient with recent MI causes more deaths than rebleeding — restart early with PPI cover and document the rationale.

High-Yield Associations and Rapid-Fire Clinical Facts

Duodenal ulcer > gastric ulcer prevalence; duodenal pain relieved by food, gastric pain worsened.

Duodenal ulcers: H. pylori in ~90%; almost never malignant; do not need follow-up biopsy.

Gastric ulcers: H. pylori in ~70%; always biopsy to exclude cancer; repeat EGD 8–12 weeks.

Posterior duodenal ulcer → bleeding from gastroduodenal artery.

Anterior duodenal ulcer → perforation (free air under diaphragm).

H. pylori is urease-positive, oxidase-positive, catalase-positive, gram-negative spiral rod.

H. pylori-associated diseases: PUD, gastric adenocarcinoma (intestinal type), MALT lymphoma, atrophic gastritis, IDA, ITP, B12 deficiency.

MALT lymphoma: low-grade, stage I/II → H. pylori eradication alone induces remission in ~70%.

Test of cure: UBT or stool antigen, 4 weeks post-antibiotics, 2 weeks off PPI. Serology not useful.

Bismuth quadruple x 14 days is preferred first-line in US (resistance trends).

Clarithromycin triple only if local resistance <15% AND no prior macrolide.

Misoprostol prevents NSAID ulcers; contraindicated in pregnancy (abortifacient).

Sucralfate: needs acidic environment; separate from antacids and other drugs by 2 hours.

PPI + clopidogrel: use pantoprazole (least CYP2C19 inhibition).

Hypokalemic hypochloremic metabolic alkalosis + paradoxical aciduria = gastric outlet obstruction.

BUN/Cr ratio >30 in bleeding → upper GI source.

Zollinger-Ellison: multiple/distal ulcers + diarrhea; fasting gastrin >1000 pg/mL off PPI; secretin stimulation if 100–1000; check MEN1 screening (parathyroid, pituitary, pancreas).

Restrictive transfusion in UGIB: target Hgb 7–9.

Aspirin resume within 1–7 days of hemostasis if for secondary CV prevention.

Forrest classification: Ia spurting, Ib oozing, IIa visible vessel, IIb adherent clot, IIc flat spot, III clean base; Ia–IIb get endoscopic therapy + IV PPI infusion.

Stress ulcer prophylaxis ICU: mechanical ventilation >48h or coagulopathy.

Curling ulcer = burn patient; Cushing ulcer = head injury (vagal-mediated).

Dieulafoy lesion ≠ peptic ulcer — large submucosal artery, brisk UGIB, often without ulcer.

Board pearl: Recurrent ulcer after confirmed H. pylori eradication and no NSAID use → think ZES, not "failed eradication."

Board Question Stem Patterns

Stem 1 — Test-and-treat: 42-year-old with 3 months epigastric pain, no alarms, stool antigen positive → bismuth quadruple therapy x 14 days, confirm eradication with UBT 4 weeks later. Distractors: empiric PPI alone, immediate EGD, serology testing.

Stem 2 — Alarm features: 67-year-old with new dyspepsia, 8 kg weight loss, microcytic anemia → EGD first (not test-and-treat). Distractor: trial PPI.

Stem 3 — Bleeding ulcer initial management: hematemesis, BP 92/60, HR 118 → two large-bore IVs, IV PPI bolus + infusion, T&C, NPO, GI consult for EGD within 24h, restrictive transfusion Hgb <7.

Stem 4 — False-negative testing: patient on omeprazole has negative stool antigen, persistent symptoms → hold PPI 2 weeks, repeat testing (or biopsy at EGD).

Stem 5 — Pregnancy: pregnant patient with PUD-like pain → sucralfate or pantoprazole; defer H. pylori eradication; avoid bismuth, tetracycline, misoprostol.

Stem 6 — Aspirin resumption: 70-year-old with recent MI on ASA develops bleeding ulcer, endoscopically controlled → resume aspirin in 1–7 days + daily PPI long-term. Distractor: stop aspirin permanently.

Stem 7 — Clopidogrel + PPI: post-stent patient on clopidogrel needing acid suppression → pantoprazole. Distractor: omeprazole.

Stem 8 — ZES: multiple duodenal ulcers + diarrhea, refractory to PPI → fasting serum gastrin off PPI; if 100–1000 → secretin stimulation. Check MEN1.

Stem 9 — Gastric ulcer follow-up: healed-appearing gastric ulcer, H. pylori eradicated → repeat EGD in 8–12 weeks with biopsies.

Stem 10 — Failed first-line: persistent H. pylori after clarithromycin triple → bismuth quadruple (or levofloxacin-based); never repeat clarithromycin.

Stem 11 — Perforation: sudden epigastric pain, rigid abdomen, free air on CXR → NPO, IVF, IV PPI, broad-spectrum antibiotics, emergent surgery. Distractor: urgent EGD.

Stem 12 — Gastric outlet obstruction: postprandial nonbilious emesis, succussion splash, hypokalemic hypochloremic alkalosis → NG decompression, electrolyte repletion, EGD with balloon dilation, eradicate H. pylori.

Stem 13 — MALT lymphoma: gastric biopsy lymphoepithelial lesions, H. pylori positive → eradicate H. pylori as first-line; surveillance EGD.

Stem 14 — Functional dyspepsia: normal EGD, H. pylori negative, persistent symptoms → PPI trial, then low-dose TCA.

CCS pearl: Time-management trap — in a bleeding patient, ordering NG lavage before EGD wastes time and is no longer standard. Move directly to resuscitation + IV PPI + GI consult.

Board pearl: When a stem mentions "patient took clarithromycin for pneumonia last year," bismuth quadruple is the correct eradication regimen — prior macrolide exposure predicts resistance.

One-Line Recap

Bottom line: Peptic ulcer disease is overwhelmingly driven by H. pylori and NSAIDs — diagnose with non-invasive testing in patients <60 without alarms (or EGD if alarms/age ≥60), treat H. pylori with 14-day bismuth quadruple therapy as default first-line, eradicate while simultaneously discontinuing NSAIDs and adding PPI for 4–8 weeks, and always confirm eradication 4 weeks post-therapy off PPI.

Diagnostic triage: <60 + no alarms → test-and-treat (UBT or stool antigen); ≥60 or alarms (bleeding, anemia, weight loss, dysphagia, vomiting, mass) → EGD with biopsies. Gastric ulcers always biopsied; repeat EGD at 8–12 weeks to confirm healing and rule out malignancy.

Treatment defaults: Bismuth quadruple (PPI + bismuth + tetracycline + metronidazole) x 14 days as first-line in the US given clarithromycin resistance; reserve clarithromycin triple for documented low-resistance areas with no prior macrolide. Salvage with levofloxacin or rifabutin regimens — never repeat the failed antibiotic.

Bleeding ulcer management: Resuscitate, IV PPI bolus + infusion, restrictive transfusion to Hgb 7, EGD within 24 hours with dual hemostatic therapy for Forrest Ia–IIb, restart aspirin within 1–7 days for secondary CV prevention with lifelong PPI coverage, and arrange GI follow-up + test-of-cure before discharge to close the safety loop.

Key traps: false-negative H. pylori testing from active PPI/antibiotics, ZES in refractory/multiple ulcers, missing MI by anchoring on dyspepsia in older patients, stopping antiplatelets permanently post-bleed, and using serology for test of cure — all classic Step 3 distractors that hinge on remembering the why, not just the what.